Drugs / ONO-4538HSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06548217 | May 2024 → Feb 2028 expected | — | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-4538HSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548217 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06548217 ↗ |